Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludovic Lacroix

Showing results (131-140 of 180) with videos related to

Pageof 18
Sort By:
Science Advances|November 8, 2023
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8<sup>+</sup> T cells in patients with advanced NSCLCMarie Naigeon, Matthieu Roulleaux Dugage, François-Xavier Danlos, et al.
British Journal of Cancer|August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitorsMarie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2016
Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01)Vania Tacher, Marie-Cécile Le Deley, Antoine Hollebecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung CancerFilippo G Dall'Olio, Wael Zrafi, Damien Vasseur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid CancerSophie Leboulleux, Christine Do Cao, Slimane Zerdoud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2017
Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification TrialAnne C Harttrampf, Ludovic Lacroix, Marc Deloger, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
Molecular screening for a personalized treatment approach in advanced adrenocortical cancerMaria Cristina De Martino, Abir Al Ghuzlan, Sebastien Aubert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2)Jacques Cadranel, Audrey Mauguen, Michele Faller, et al.
Oncotarget|March 9, 2018
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancersLuc Cabel, Alina Fuerea, Ludovic Lacroix, et al.
Pageof 18

Showing results (131-140 of 180) with videos related to

Sort By:
Pageof 18
Science Advances|November 8, 2023
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8<sup>+</sup> T cells in patients with advanced NSCLCMarie Naigeon, Matthieu Roulleaux Dugage, François-Xavier Danlos, et al.
British Journal of Cancer|August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitorsMarie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2016
Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01)Vania Tacher, Marie-Cécile Le Deley, Antoine Hollebecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung CancerFilippo G Dall'Olio, Wael Zrafi, Damien Vasseur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid CancerSophie Leboulleux, Christine Do Cao, Slimane Zerdoud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2017
Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification TrialAnne C Harttrampf, Ludovic Lacroix, Marc Deloger, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
Molecular screening for a personalized treatment approach in advanced adrenocortical cancerMaria Cristina De Martino, Abir Al Ghuzlan, Sebastien Aubert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2)Jacques Cadranel, Audrey Mauguen, Michele Faller, et al.
Oncotarget|March 9, 2018
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancersLuc Cabel, Alina Fuerea, Ludovic Lacroix, et al.
Pageof 18